Regentatlantic Capital LLC Sells 100 Shares of Edge Therapeutics, Inc. (EDGE)
Regentatlantic Capital LLC decreased its stake in shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 134,900 shares of the biotechnology company’s stock after selling 100 shares during the period. Regentatlantic Capital LLC owned 0.44% of Edge Therapeutics worth $1,384,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of EDGE. State Street Corp raised its position in Edge Therapeutics by 5.7% in the fourth quarter. State Street Corp now owns 200,301 shares of the biotechnology company’s stock valued at $2,505,000 after buying an additional 10,859 shares in the last quarter. Trexquant Investment LP purchased a new position in Edge Therapeutics during the first quarter valued at about $143,000. Spark Investment Management LLC purchased a new position in Edge Therapeutics during the first quarter valued at about $157,000. TFS Capital LLC purchased a new position in Edge Therapeutics during the first quarter valued at about $209,000. Finally, Teachers Advisors LLC raised its position in Edge Therapeutics by 8.2% in the fourth quarter. Teachers Advisors LLC now owns 28,353 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 2,150 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.
Edge Therapeutics, Inc. (NASDAQ EDGE) opened at 10.44 on Monday. The company’s 50-day moving average is $10.30 and its 200-day moving average is $9.79. Edge Therapeutics, Inc. has a 52-week low of $7.30 and a 52-week high of $13.50. The firm’s market capitalization is $321.85 million.
Edge Therapeutics (NASDAQ:EDGE) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.44). On average, analysts predict that Edge Therapeutics, Inc. will post ($1.87) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Regentatlantic Capital LLC Sells 100 Shares of Edge Therapeutics, Inc. (EDGE)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/07/regentatlantic-capital-llc-cuts-stake-in-edge-therapeutics-inc-edge-updated.html.
A number of equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research lowered shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday.
In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $10.19, for a total transaction of $76,425.00. Following the sale, the insider now directly owns 132,736 shares of the company’s stock, valued at $1,352,579.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 36.19% of the stock is currently owned by corporate insiders.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.